Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.
Nardin S, Mora E, Varughese FM, et al. Breast cancer survivorship, quality of life, and late toxicities. Front Oncol 2020;10:864.
Wishart GC, Bajdik CD, Azzato EM, et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol 2011;37:411–417.
Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 2010;12:R1.
Gray E, Marti J, Brewster DH, et al. Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data. Br J Cancer 2018;119:808–814.
American College of Surgeons. National Cancer Database. Accessed July 27, 2020. Available at: https://www.facs.org/quality-programs/cancer/ncdb
Su C, Peng C, Agbodza E, et al. Publication trend, resource utilization, and impact of the US National Cancer Database: a systematic review. Medicine (Baltimore) 2018;97:e9823.
Wishart GC, Bajdik CD, Dicks E, et al. PREDICT plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012;107:800–807.
Candido Dos Reis FJ, Wishart GC, Dicks E, et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res 2017;19:58.
American College of Surgeons. Participant user files. Accessed September 2, 2022. Available at: https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/puf/
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474.
Tramonti G. nhs.predict: breast cancer survival and therapy benefits. Accessed September 2, 2022. Available at: https://CRAN.R-project.org/package=nhs.predict
Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol 2017;17:53.
Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMC Med 2015;13:1.
Cao L, Stabellini N, Towe CW, et al. Independent validation of the PREDICT prognostication tool in U.S. breast cancer patients using the National Cancer Database (NCDB). J Natl Compr Canc Netw 2022;20:Abstract BPI22-014.
Stabellini N, Cullen J, Cao L, et al. Racial disparities in breast cancer treatment patterns and treatment related adverse events. Sci Rep 2023;13:1233.
Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980–991.
Engelhardt EG, Pieterse AH, van Duijn-Bakker N, et al. Breast cancer specialists’ views on and use of risk prediction models in clinical practice: a mixed methods approach. Acta Oncol 2015;54:361–367.
Engelhardt EG, van den Broek AJ, Linn SC, et al. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. Eur J Cancer 2017;78:37–44.
Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin 2016;66:370–374.
van Maaren MC, van Steenbeek CD, Pharoah PD, et al. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population. Eur J Cancer 2017;86:364–372.
Zaguirre K, Kai M, Kubo M, et al. Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients. Cancer Med 2021;10:1605–1613.
de Glas NA, Bastiaannet E, Engels CC, et al. Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. Br J Cancer 2016;114:395–400.
Maishman T, Copson E, Stanton L, et al. An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ≤40 years at breast cancer diagnosis. Br J Cancer 2015;112:983–991.
National Health Service, Predict Breast Cancer. What is PREDICT? Accessed September 2, 2022. Available at: https://breast.predict.nhs.uk/
Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717–729.
Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst 2011;103:1656–1664.
Niikura N, Masuda S, Kumaki N, et al. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clin Breast Cancer 2014;14:323–329.e3.